IQVIA (NYSE:IQV) Price Target Raised to $325.00

IQVIA (NYSE:IQV) had its target price boosted by equities researchers at JPMorgan Chase & Co. from $295.00 to $325.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 17.44% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. UBS Group assumed coverage on shares of IQVIA in a research report on Wednesday, September 30th. They set a “buy” rating and a $345.00 price target for the company. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Evercore raised their price target on shares of IQVIA from $275.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. BMO Capital Markets lifted their price target on shares of IQVIA from $270.00 to $305.00 in a report on Monday, October 19th. Finally, Leerink Partners boosted their price objective on shares of IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $285.35.

IQVIA Price Performance

Shares of IQV traded up $5.18 during mid-day trading on Wednesday, hitting $276.73. The company’s stock had a trading volume of 982,081 shares, compared to its average volume of 1,691,587. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a 50-day simple moving average of $264.74 and a 200 day simple moving average of $209.94. The firm has a market capitalization of $45.55 billion, a P/E ratio of 34.29, a P/E/G ratio of 2.46 and a beta of 1.17. IQVIA has a 1-year low of $154.50 and a 1-year high of $284.50.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping analysts’ consensus estimates of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. IQVIA’s quarterly revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.00 earnings per share. Analysts predict that IQVIA will post 11.54 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider W. Richard Staub sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 10,023 shares of company stock valued at $2,413,394. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of IQVIA during the 2nd quarter valued at $2,811,292,000. Dimensional Fund Advisors LP boosted its holdings in IQVIA by 4.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock valued at $282,657,000 after acquiring an additional 66,643 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in IQVIA by 9.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in IQVIA in the second quarter valued at $240,911,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in IQVIA by 8.3% during the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,225,851 shares of the medical research company’s stock valued at $209,057,000 after acquiring an additional 93,779 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Key IQVIA News

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Third-quarter earnings and revenue exceeded expectations. IQVIA reported adjusted EPS of $3.34, above the $3.26 consensus estimate, while revenue rose 8% year over year to approximately $4.43 billion, ahead of the $4.37 billion forecast. EPS increased from $3.00 in the year-ago quarter. IQVIA Reports Third-Quarter 2026 Results
• Positive Sentiment: Management raised its fiscal 2026 guidance. IQVIA now expects revenue of $17.35 billion to $17.50 billion and adjusted EPS of $12.90 to $13.00. The revenue range brackets the roughly $17.41 billion analyst consensus, indicating confidence that recent operating momentum will continue. IQVIA Holdings Boosts FY26 Outlook
• Positive Sentiment: Clinical demand and bookings provided encouraging forward indicators. Clinical bookings reached $11.7 billion on a trailing-12-month basis, described as the strongest level since 2022. Strong R&D Solutions performance, improved execution and robust bookings were key drivers of the quarterly beat. IQVIA Signals 2026 Outlook
• Positive Sentiment: Deutsche Bank raised its price target to $310 from $300 and maintained a Buy rating, reinforcing the view that the earnings beat and upgraded outlook could support additional upside. Deutsche Bank Adjusts IQVIA Price Target
• Neutral Sentiment: Despite the strong results, some early trading commentary indicated initial hesitation, suggesting investors may have already priced in part of the earnings improvement. The subsequent guidance increase and analyst price-target hike provided stronger support for the stock.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.